Literature DB >> 17439243

Oxidative folding and N-terminal cyclization of onconase.

Ervin Welker1, Laura Hathaway, Guoqiang Xu, Mahesh Narayan, Lovy Pradeep, Hang-Cheol Shin, Harold A Scheraga.   

Abstract

Cyclization of the N-terminal glutamine residue to pyroglutamic acid in onconase, an anti-cancer chemotherapeutic agent, increases the activity and stability of the protein. Here, we examine the correlated effects of the folding/unfolding process and the formation of this N-terminal pyroglutamic acid. The results in this study indicate that cyclization of the N-terminal glutamine has no significant effect on the rate of either reductive unfolding or oxidative folding of the protein. Both the cyclized and uncyclized proteins seem to follow the same oxidative folding pathways; however, cyclization altered the relative flux of the protein in these two pathways by increasing the rate of formation of a kinetically trapped intermediate. Glutaminyl cyclase (QC) catalyzed the cyclization of the unfolded, reduced protein but had no effect on the disulfide-intact, uncyclized, folded protein. The structured intermediates of uncyclized onconase were also resistant to QC catalysis, consistent with their having a native-like fold. These observations suggest that, in vivo, cyclization takes place during the initial stages of oxidative folding, specifically, before the formation of structured intermediates. The competition between oxidative folding and QC-mediated cyclization suggests that QC-catalyzed cyclization of the N-terminal glutamine in onconase occurs in the endoplasmic reticulum, probably co-translationally.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439243      PMCID: PMC2535829          DOI: 10.1021/bi602495a

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  73 in total

1.  Two new structured intermediates in the oxidative folding of RNase A.

Authors:  E Welker; M Narayan; M J Volles; H A Scheraga
Journal:  FEBS Lett       Date:  1999-11-05       Impact factor: 4.124

2.  Enzymatic cyclization of L-glutamine and L-glutaminyl peptides.

Authors:  M MESSER
Journal:  Nature       Date:  1963-03-30       Impact factor: 49.962

3.  The importance of dynamic effects on the enzyme activity: X-ray structure and molecular dynamics of onconase mutants.

Authors:  Antonello Merlino; Lelio Mazzarella; Anna Carannante; Anna Di Fiore; Alberto Di Donato; Eugenio Notomista; Filomena Sica
Journal:  J Biol Chem       Date:  2005-02-22       Impact factor: 5.157

Review 4.  Biochemistry of frog ribonucleases.

Authors:  M Irie; K Nitta; T Nonaka
Journal:  Cell Mol Life Sci       Date:  1998-08       Impact factor: 9.261

5.  NMR structural characterization and computational predictions of the major intermediate in oxidative folding of leech carboxypeptidase inhibitor.

Authors:  Joan L Arolas; Loyola D'Silva; Grzegorz M Popowicz; Francesc X Aviles; Tad A Holak; Salvador Ventura
Journal:  Structure       Date:  2005-08       Impact factor: 5.006

6.  Evidence for tissue-specific forms of glutaminyl cyclase.

Authors:  P A Sykes; S J Watson; J S Temple; R C Bateman
Journal:  FEBS Lett       Date:  1999-07-16       Impact factor: 4.124

7.  Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV.

Authors:  E Van Coillie; P Proost; I Van Aelst; S Struyf; M Polfliet; I De Meester; D J Harvey; J Van Damme; G Opdenakker
Journal:  Biochemistry       Date:  1998-09-08       Impact factor: 3.162

8.  In vitro refolding/unfolding pathways of amphioxus insulin-like peptide: implications for folding behavior of insulin family proteins.

Authors:  Yan Chen; Rui Jin; Hong-Yun Dong; You-Min Feng
Journal:  J Biol Chem       Date:  2004-10-22       Impact factor: 5.157

Review 9.  Low-density lipoprotein receptor structure and folding.

Authors:  J Gent; I Braakman
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

10.  Total chemical synthesis and oxidative folding of delta-conotoxin PVIA containing an N-terminal propeptide.

Authors:  Pawel Buczek; Olga Buczek; Grzegorz Bulaj
Journal:  Biopolymers       Date:  2005       Impact factor: 2.505

View more
  8 in total

1.  Structural and functional insights into Aeropyrum pernix OppA, a member of a novel archaeal OppA subfamily.

Authors:  M Balestrieri; M Gogliettino; I Fiume; G Pocsfalvi; G Catara; M Rossi; G Palmieri
Journal:  J Bacteriol       Date:  2010-11-19       Impact factor: 3.490

2.  A circularly permuted beta-lactamase as a novel reporter for evaluation of protein cyclization efficiency.

Authors:  Jeong Seon Kwon; Jyotiranjan Bal; Hai Min Hwang; Jeong-Yoon Kim
Journal:  J Microbiol       Date:  2008-08-31       Impact factor: 3.422

Review 3.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Authors:  W Ardelt; K Shogen; Z Darzynkiewicz
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

Review 4.  Ribonucleases as novel chemotherapeutics : the ranpirnase example.

Authors:  J Eugene Lee; Ronald T Raines
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

Review 5.  Ribonucleases as potential modalities in anticancer therapy.

Authors:  Wojciech Ardelt; Barbara Ardelt; Zbigniew Darzynkiewicz
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

6.  Dissimilarity in the oxidative folding of onconase and ribonuclease A, two structural homologues.

Authors:  Robert F Gahl; Mahesh Narayan; Guoqiang Xu; Harold A Scheraga
Journal:  Protein Eng Des Sel       Date:  2008-01-31       Impact factor: 1.650

7.  Onconase cytotoxicity relies on the distribution of its positive charge.

Authors:  Rebecca F Turcotte; Luke D Lavis; Ronald T Raines
Journal:  FEBS J       Date:  2009-06-11       Impact factor: 5.542

8.  Linked production of pyroglutamate-modified proteins via self-cleavage of fusion tags with TEV protease and autonomous N-terminal cyclization with glutaminyl cyclase in vivo.

Authors:  Yan-Ping Shih; Chi-Chi Chou; Yi-Ling Chen; Kai-Fa Huang; Andrew H-J Wang
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.